Displaying 36 - 40 of 50
Wed 24 April 2013
The All Party Parliamentary Group on pancreatic cancer (APPG) has announced the launch of a special inquiry. It will look at pancreatic cancer survival rates and investigate why rates of survival from the disease, at around 4%, remain the lowest of all the 21 most common cancers in the UK.Read More about 'Parliamentary inquiry into pancreatic cancer launched'
Thu 21 March 2013
Progress on tackling pancreatic cancer continues to lag behind other cancers despite being the 5th most common cause of cancer death in the UK.Read More about 'Progress on pancreatic cancer still lags behind other cancers'
Wed 23 January 2013
Further details of a 2012 study have shown patients who received Abraxane in combination with the chemotherapy agent gemcitabine had an overall survival of 8.5 months.Read More about 'Cancer drug extends survival by nearly two months'
Mon 12 November 2012
In a Phase III study, Celgene's ABRAXANE® (NAB-PACLITAXEL), currently approved for breast and lung cancer, has been found to improve overall survival for patients with advanced pancreatic cancer.Read More about 'Cancer drug extends survival in patients with advanced pancreatic cancer'
Sun 11 November 2012
Clovis Oncology has announced the results from its LEAP study of CO-101 versus gemcitabine in metastatic pancreatic cancer.Read More about 'Negative outcome of pancreatic cancer study announced'